TRAV1-2 and myeloid sarcoma: Of note, frequency of TRAV1-2+ CD161low and TRAV1-2+ CD161− or TRAV1-2− CD161high cell populations did not differ between MS patients and HCs, suggesting that reduced MAIT cell numbers in MS patients were not due to down-modulation of TRAV1-2+ TCR or CD161 molecules in MAIT cells of MS patients.